HCW Biologics is trading at $1.36, down 8.09%, with no specific company announcement identified to explain the October 13 decline.
- The latest reported company news was October 9: FDA guidance on preparing an IND application for its solid-tumor candidate, with filing still targeted for the first half of 2027. That update does not establish a cause for the current decline.
- The provided broad-market moves do not show a comparable, same-direction decline to explain the move.